Sector: MedicalIPXL (OTCBB: IPXL)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 32 |
Technical : | 216 |
Performance : | 64 |
Overall: | 65 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 236 |
Technical : | 188 |
Performance : | 81 |
Overall: | 193 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 235 |
Technical : | 230 |
Performance : | 90 |
Overall: | 224 |
Number of Stocks: | 306 |
Headlines
- Impax Laboratories Drives Stronger Performance with IBM Business Analytics
Nov 20, 2009 09:01 AM | IBM, IPXL
- Impax Laboratories to Present at the Credit Suisse 18th Annual Healthcare Conference
Nov 10, 2009 04:14 PM | IPXL
- Impax Laboratories Confirms Patent Challenge Relating to TRICOR(R) 48mg and 145mg Tablets
Oct 30, 2009 10:45 AM | ABT, IPXL
- Impax Pharmaceuticals Initiates Second Phase III Trial of IPX066 in Parkinson's Disease
Oct 26, 2009 09:09 AM | IPXL
- Impax Laboratories Settles Pending Litigation for FLOMAX(R)
Oct 07, 2009 07:00 AM | IPXL
- Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX(R) 0.4mg Capsules
Oct 05, 2009 08:01 AM | IPXL
- Impax Laboratories Commences Shipment of Generic Adderall XR(R) Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Oct 01, 2009 03:46 PM | IPXL
- BioMed News Bytes: CUR, IPXL, QCOR, VRX
Sep 21, 2009 11:49 AM | GSK, IPXL, VRX
- Impax Laboratories Confirms Patent Challenge Relating to ORACEA(R) Delayed-Release Capsules, 40mg
Sep 21, 2009 07:00 AM | IPXL
- StoredIQ Shares Expertise at IQPC's eDiscovery Pharma, Biotech and Medical Device Conference
Sep 10, 2009 09:01 AM | IPXL
- Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009
Nov 03, 2009 07:52 AM | IPXL
- Impax Laboratories Confirms Patent Challenge Relating to TRICOR® 48mg and 145mg Tablets
Oct 30, 2009 10:52 AM | ABT, IPXL
- Impax Laboratories to Host Third Quarter 2009 Earnings Conference Call and Webcast on November 3
Oct 13, 2009 04:51 PM | IPXL
- Impax Laboratories Settles Pending Litigation for FLOMAX®
Oct 07, 2009 07:54 AM | IPXL
- Impax Laboratories Commences Shipment of Generic Adderall XR® Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Oct 01, 2009 03:54 PM | IPXL, SHPGY
- Impax Laboratories to Present at the JMP Securities Healthcare Focus Conference
Sep 28, 2009 03:54 PM | IPXL
- Impax Laboratories Confirms Patent Challenge Relating to ORACEA® Delayed-Release Capsules, 40mg
Sep 21, 2009 07:51 AM | IPXL
- Impax to Present at the UBS Global Life Sciences Conference
Sep 16, 2009 03:51 PM | IPXL
- Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease
Aug 20, 2009 09:53 AM | IPXL, OMCM
- Impax Laboratories Receives Final FDA Approval for Generic Depakote® Extended-Release 500mg Tablets
Aug 05, 2009 01:53 PM | ABT, IPXL
- Form 4 IMPAX LABORATORIES INC For: Jun 08 Filed by: NESTOR MICHAEL (10K)
Nov 12, 2009 07:50 PM
- Form 4 IMPAX LABORATORIES INC For: Nov 06 Filed by: MARKBREITER MICHAEL (10K)
Nov 09, 2009 05:34 PM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: OH KIM SUN (10K)
May 22, 2009 01:48 PM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: MARKBREITER MICHAEL (10K)
May 22, 2009 01:44 PM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: BENET LESLIE Z (10K)
May 22, 2009 01:43 PM
- Form 4 FLEMING NIGEL For: May 20 (10K)
May 22, 2009 01:38 PM
- Form 4 TERRERI PETER R For: May 20 (10K)
May 22, 2009 10:26 AM
- Form 4 KOCH ARTHUR A JR For: May 20 (10K)
May 22, 2009 10:26 AM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: NESTOR MICHAEL (10K)
May 22, 2009 10:25 AM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: BURR ROBERT L (10K)
May 22, 2009 10:06 AM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
IPXL
|
Compare to S&P
|
| YTD |
-0.01 %
|
-0.01 %
|
| 4 Weeks |
16.86 %
|
15.60 %
|
| 12 Weeks |
45.62 %
|
37.29 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 120.00 %
|
|
EPS Growth in Last Year: 173.33 %
|
|
Sales Growth in Last Quarter: 11.18 %
|
|
Sales Growth in Last Quarter: 76.61 %
|
|
